Incoming prime minister vows to defend UK pharma | Thyroid drug left off Britain's Cancer Drugs Fund list | Cost of HCV treatment associated with SVR
July 14, 2016
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
Top Story
Incoming prime minister vows to defend UK pharma
Incoming British Prime Minister Theresa May said the government should defend Britain's pharmaceutical sector from takeovers, citing AstraZeneca's successful resistance to a 2014 takeover bid by Pfizer.
Bloomberg (7/11) 
LinkedIn Twitter Facebook Google+ Email
10 Questions to ask before choosing a cloud-based ERP solution
How do you know if a cloud-based solution suits your business? And more importantly, how do you find the right match? This whitepaper features 10 important questions you should ask to identify the best cloud-based ERP for your company. Click here to read the white paper.
Thyroid drug left off Britain's Cancer Drugs Fund list
Patients in England with advanced thyroid cancer face delays in receiving Eisai's drug Lenvima, or lenvatinib, because it was left out of the revised Cancer Drugs Fund, according to the company. Eisai urged the National Health Service to find an interim solution to allow access to the drug.
PharmaTimes (U.K.) (7/12) 
LinkedIn Twitter Facebook Google+ Email
Cost of HCV treatment associated with SVR
A recent Swiss study found that as the cost of hepatitis C treatment rose, so did the rate of sustained viral response. In the US, each additional percentage point of SVR was associated with an incremental cost of $1063.81 for treatment.
Specialty Pharmacy Times (7/12) 
LinkedIn Twitter Facebook Google+ Email
Study examines how mutation triggers blood cancer in infants
Scientists with Scotland's University of Edinburgh Medical Research Council Centre for Regenerative Medicine studied the effects of the fusion gene MLL4-AF4 in embryonic mice to better understand the development of infant acute lymphoblastic leukemia, according to a study in the journal Cell Reports. In embryos with an inactive form of the fusion gene, the expression of enzymes that activate the gene resulted in a preleukaemic state of increased production of white blood cells.
Voice Online (U.K.) (7/8) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
Celyad, Ono sign cancer immunotherapy licensing deal
Celyad granted Ono Pharmaceuticals an exclusive license that will expand the global presence of Celyad's allogeneic NKR-2 T-cell immunotherapy targeting solid and hematological tumors to South Korea, Japan and Taiwan. Celyad is entitled to receive an upfront payment of $12.5 million and as much as $299 million in milestone fees and double-digit sales royalties.
Genetic Engineering & Biotechnology News (7/11) 
LinkedIn Twitter Facebook Google+ Email
North America
Top FDA officials: US needs better tracking system for medical devices
The US should integrate the National Evaluation System for Health Technology with EHRs, device registries developed by professional societies, claims databases and federal data collection initiatives to improve tracking and reporting of safety issues with medical devices, FDA Commissioner Robert Califf and Center for Devices and Radiological Health Director Jeffrey Shuren wrote in an article for the Journal of the American Medical Association. The system would allow for faster and cheaper generating of data to back approval decisions, reimbursement actions and payer coverage, they wrote.
Regulatory Focus (7/11), (free registration) (7/11) 
LinkedIn Twitter Facebook Google+ Email
Final guidance on proving medtech electromagnetic compatibility released by FDA
A final guidance has been released by the FDA outlining the information medical device makers need to submit to support the electromagnetic compatibility of their products in applications for premarket approval, humanitarian device exemption, premarket notification, investigational device exemption and de novo requests. Companies are advised to use the guidance along with consensus standards and other device-specific FDA guidance documents.
Med Device Online (7/12) 
LinkedIn Twitter Facebook Google+ Email
Price of overdose-intervention drug rose up to 60% in 2014
As naloxone has been made more readily available, the cost of the overdose-intervention drug has climbed substantially. Amphastar, one of the two major manufacturers of naloxone in the US, increased prices for naloxone outpatient use by 60% in 2014, while Hospira, a major naloxone manufacturer acquired by Pfizer, raised the costs of its smaller-dose naloxone by about 50%.
WBAA-AM/FM (West Lafayette, Ind.) (7/12) 
LinkedIn Twitter Facebook Google+ Email
Biosimilar threat to biotech firms is real but distant
Less expensive biosimilars of such drugs as AbbVie's Humira and Amgen's Enbrel may soon receive FDA approval, but patent issues and other hurdles may delay their entry into the marketplace for years. AbbVie, for example, doesn't expect a biosimilar competitor until 2022.
The Wall Street Journal (tiered subscription model) (7/12) 
LinkedIn Twitter Facebook Google+ Email
Sagent Pharmaceuticals signs acquisition deal with Japanese firm
Sagent Pharmaceuticals will be acquired by Japanese drugmaker Nichi-Iko Pharmaceutical for $736 million. The deal, which is expected to close by March 2017, will support Nichi-Iko's biosimilar product pipeline marketing efforts in the US and boost its presence in injectable products and generic drugs.
The Wall Street Journal (tiered subscription model) (7/11),  Genetic Engineering & Biotechnology News (7/11) 
LinkedIn Twitter Facebook Google+ Email
DIA News
Advance thought leadership in the new July Journal
DIA members receive access to our peer-reviewed journal, Therapeutic Innovation & Regulatory Science. This issue's topics include:
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
A failure is a man who has blundered but is not able to cash in on the experience.
Elbert Hubbard,
writer and artist
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information